Jubilant Life Sciences (Shanghai) Limited Balance Sheet as at 31 March 2019

		RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
			As at		at
	Notes	31 Mar	ch 2019	31 Mar	ch 2018
ASSETS					
Non-current assets					
Property, plant and equipment	1	49,801	512	67,112	697
Total non-current assets		49,801	512	67,112	697
Current assets					
Inventories	2	15,863,466	163,235	12,640,179	131,205
Financial assets					
i. Trade receivables	3	2,202,275	22,661	10,648,730	110,534
ii. Cash and cash equivalents	4	4,269,778	43,936	6,488,634	67,352
iii. Other financial assets	5	12,278,349	126,344	11,805,816	122,544
Current tax assets	6	895,973	9,220	54,544	566
Deferred tax assets (Net)		343,439	3,534	*	<u>_</u>
Other current assets	7	509,820	5,246	1,312,349	13,622
Total current assets		36,363,100	374,176	42,950,252	445,823
Total assets		36,412,901	374,688	43,017,364	446,520
EQUITY AND LIABILITIES					
Equity					
Equity share capital	8	1,652,837	8,804	1,652,837	8,804
Other equity		21,363,400	228,032	22,393,717	240,799
Total equity		23,016,237	236,836	24,046,554	249,603
LIABILITIES					
Current liabilities					
Financial liabilities					
i. Trade payables	9	13,377,440	137,654	18,941,615	196,614
Other current liabilities	10	19,224	198	29,195	303
Total current liabilities		13,396,664	137,852	18,970,810	196,917
Total liabilities		13,396,664	137,852	18,970,810	196,917
Total equity and liabilities		36,412,901	374,688	43,017,364	446,520

Sanjay Das

Vice President - Corporate Accounts

Place: Noida Date: 10 May 2019

		RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
	Notes	For the year end	led 31 March 2019	For the year en	ded 31 March 2018
Revenue from operations	11	96,306,922	1,002,558	134,141,337	1,310,655
Other income	12	17,046	178	23,885	231
Total income		96,323,968	1,002,736	134,165,222	1,310,886
Expenses					
Purchases of stock-in-trade	13	89,016,310	927,036	126,028,091	1,230,670
Changes in inventories of stock-in-trade	14	(3,223,287)	(33,992)	(1,403,027)	(11,834)
Employee benefits expense	15	4,658,339	48,490	3,907,430	38,047
Finance costs	16	586,020	6,102	850,256	8,345
Depreciation and amortisation expense	18	26,190	273	27,114	264
Other expenses	17	6,634,152	68,972	2,721,788	26,251
Total expenses		97,697,724	1,016,881	132,131,652	1,291,743
(Loss)/ profit before tax		(1,373,756)	(14,145)	2,033,570	19,143
Tax expense					
- Current tax		4	72	91,808	869
- Deferred tax		(343,439)	(3,536)	4	(4)
Total tax expense		(343,439)	(3,536)	91,808	869
(Loss)/ profit for the year	-	(1,030,317)	(10,609)	1,941,762	18,274
Other comprehensive income					
Items that will not be reclassified to profit or le	OSS				
Exchange differences on translation of foreign operations		÷	(2,158)	멸	23,323
Total other comprehensive income for the year to fax	ear,	3	(2,158)	Ī	23,323
Total comprehensive (loss)/ income for the y	ear	(1,030,317)	(12,767)	1,941,762	41,597

Sanjay Das Vice President - Corporate Accounts

Place: Noida Date: 10 May 2019

Jubilant Life Sciences (Shanghai) Limited Statement of changes in Equity for the year ended 31st March 2019

A. Equity share capital

a) Equity share capital	No. of shares	RMB	INR (₹ In Thousands)
Balance as at 1 April 2017	200,000	1,652,837	8,804
Addition during the year	₩	4	
Balance as at 31 March 2018	200,000	1,652,837	8,804
Addition during the year	*		(4)
Balance as at 31 March 2019	200,000	1,652,837	8,804

B. Other equity									
					Reserves and sur	plus			
	Retained e	earnings	Statutor	Statutory Reserve Capital Reser		foreign operations		Т	otal
	No. of shares	INR (₹ In Thousands)	No. of shares	INR (₹ In Thousands)	No. of shares	INR (₹ In Thousands)	INR (₹ In Thousands)	No. of shares	INR (₹ In I housands)
Balance as at 1 April 2017	18,042,171	190,703	2,345,484	21,419	64,300	626	(13,546)	20,431,955	199,202
Profit for the year	1,941,762	18,274	-	·	+:			1,941,762	18,274
Transfer to Capital reserves Exchange difference on translation	1\$1				3	=	127	3	ĕ
of foreign operations	1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A 1 A	VALORITORY.		7/547	- Sweller		23,323		23,323
Balance as at 31 March 2018	19,983,933	208,977	2,345,484	21,419	64,300	626	9,777	22,393,717	240,799
Balance as at 1 April 2018	19,983,933	208,977	2,345,484	21,419	64,300	626	9,777	22,393,717	240,799
Loss for the year Exchange difference on translation	(1,030,317)	(10,609)		27	=	15	(. <u></u>	(1,030,317)	(10,609)
of foreign operations					•		(2,158)		(2,158)

21,419

64,300

7,619

21,363,400

626

228,032

Sanjay Das Vice President - Corporate Accounts Place: Noida Date: 10 May 2019

Balance as at 31 March 2019

18,953,616

198,368

2,345,484

Jubilant Life Sciences (Shanghai) Limited Statement of cash flows for the year ended 31 March 2019

	RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
	For the ye	ear ended	For the ye	ear ended
	31 Mar	ch 2019	31 Mar	
A. Cash flows from operating activities				
Net profit before tax	(1,373,756)	(14,145)	2,033,570	19,143
Adjustments:		` ′ ′		
Depreciation and amortisation expense	26,190	273	27,114	264
Finance costs	586,020	6,102	850,256	8,345
Unrealised foreign exchange loss/ (gain)	696	7	(72,535)	(706)
Interest income	(12,611)	(132)	(23,885)	(231)
	600,295	6,251	780,950	7,672
Operating cash flows before working capital changes	(773,461)	(7,894)	2,814,520	26,815
Decrease in trade accounts receivable, financial assets, other current and non-current assets	7,983,362	82,708	2,094,794	20,382
Increase in inventories	(3,223,287)	(33,393)	(1,399,969)	(13,622)
Decrease in trade payables and other current liabilities	(4,781,752)	(49,539)	(3,265,618)	(31,774)
Cash generated from operations	(795,138)	(8,118)	243,727	1,801
Income tax paid (net of refund)	(841,430)	(8,717)	(146,351)	(1,424)
Net cash generated from operating activities (A)	(1,636,568)	(16,835)	97,376	377
B. Cash flow from investing activities				
Purchase of property, plant and equipment	(8,879)	(92)		
Interest received	12,611	132	23,885	232
Net cash generated from investing activities (B)	3,732	40	23,885	232
C. Cash flow arising from financing activities				
Finance costs paid	(586,020)	(6,071)	(850,256)	(8,273)
Net cash used in financing activities (B)	(586,020)	(6,071)		
recease used in imalicing activities (b)	(580,020)	(0,071)	(850,256)	(8,273)
D. Effect of exchange rate changes	()	(549)		7,098
	(2,218,856)	(23,416)	(728,995)	(566)
Net increase/ (decrease) in cash and cash equivalents (A+B)	6 400 63 4	(7.77	# 01# COO	C# 010
Add: cash and cash equivalents at the beginning of year	6,488,634	67,352	7,217,629	67,918
Cash and cash equivalents at the end of the year	4,269,778	43,936	6,488,634	67,352

Sanjay Das

Vice President - Corporate Accounts

Place: Noida Date: 10 May 2019

Jubilant Life Sciences (Shanghai) Limited Note 1 Property, plant and equipment

INR (₹ In Thousands)

				RMB				
	Furniture &	Office			Furniture &	Office		
Description	fixtures	Equipment	Computers	Total	fixtures	Equipment	Computers	Total
Gross carrying amount Gross carrying amount as at 1 April 2017	21.373	132,245	4.838	158.456	195	1.097	84	1.340
Currency translation adjustment	`			31	20	281	2	303
Gross carrying amount as at 31 March 2018	21,373	132,245	4,838	158,456	215	1,378	20	1,643
OPOCE A P. S.	i i	CHY CH						1
Accumulated depreciation as at 1 April 2018	10,752	53,4/8	*	04,230	94	359	1	453
Depreciation charge for the year	2,900	24,214		27,114	28	236	ı	264
Currency translation adjustment	ä		-		12	217	/1	230
Accumulated depreciation as at 31 March 2019	13,652	77,692		91,344	134	812		947
Net carrying amount as at 31 March 2018	7,721	54,553	4,838	67,112	81	995	920	269
Note 1 Property, plant and equipment				RMB				INR (₹ In Thousands)
	Furniture &	Office			Furniture &	Office		
Description	fixtures	Equipment	Computers	Total	fixtures	Equipment	Computers	Total
Gross carrying amount as at 1 April 2018	21,373	132,245	4,838	158,456	215	1,378	50	1,643
Additions / adjustments	į.	,	8,879	8,879	ı	,	91	91
Deductions / adjustments	Ę.	Ľ,	ı		(2)	(32)	9	(28)
Currency translation adjustment		Q.	(i				v	
Gross carrying amount as at 31 March 2019	21,373	132,245	13,717	167,335	213	1,346	147	1,706
				1.				
Accumulated depreciation as at 1 April 2018	13,652	77,692	3	91,344	134	812	ı	947
Depreciation charge for the year	2,900	22,224	1,066	26,190	30	231	111	272
Currency translation adjustment	ï	-	(i)	-10	(1)	(24)		(25)
Accumulated depreciation as at 31 March 2019	16,552	916'66	1,066	117,534	163	1,020	11	1,194
Net carrying amount as at 31 March 2019	4,821	32,329	12,651	49,801	92	326	136	512

Jubilant Life Sciences (Shanghai) Limited Notes to the financial statements for the year ended 31 March 2019

	the manetal statements for the fear chaed of 1740.	RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
		As at 31 M	Iarch 2019	As at 31 N	1arch 2018
Note 2.	Inventories				
1	(Valued at lower of cost and net realisable value)				
	- Stock-in-trade	15,894,289	163,552	12,671,002	131,525
	Less: Provision for inventory	30,823	317	30,823	320
		15,863,466	163,235	12,640,179	131,205
FINAN	CIAL ASSET CURRENT				
Note 3.	Trade receivables				
	Other receivables				
,	Unsecured, considered good	2,202,275	22,661	10,648,730	110,534
		2,202,275	22,661	10,648,730	110,534
Note 4.	Cash and cash equivalents Balances with banks:				
	- On current accounts	4,269,778	43,936	6,488,634	67,352
		4,269,778	43,936	6,488,634	67,352
Note 5.	Other financial assets				
	Notes B/R Receivable	12,226,039	125,806	11,581,283	120,214
	- Advance recoverable in cash & kind				
	- Others	52,310	538	224,533	2,330
		12,278,349	126,344	11,805,816	122,544
Note 6.	Current tax assets				
	-Advance Payment Of Income Tax-Current	895,973	9,220	54,544	566
		895,973	9,220	54,544	566
Note 7.	Other current assets				ii.
	Deposit /Balance With sales tax-current	252,751	2,601	1,099,935	11,417
	Prepaid expenses	257,069	2,645	212,414	2,205
		509,820	5,246	1,312,349	13,622

Jubilant Life Sciences (Shanghai) Limited

Notes to financial statement for the year ended 31 March 2019

Note 8. Equity share capital

	RMB	INR in thousands	RMB	INR in thousands
	As at 31	March 2019	As at 31	March 2018
Issued, subscribed and paid up share capital				
200,000 (31 March 2018: 200,000 equity shares of USD 1 each	1,652,837	8,804	1,652,837	8,804
	1,652,837	8,804	1,652,837	8,804
a) Movement in share capital				
Equity share capital	No. of Shares		RMB	INR (₹ In Thousands)
Balance as at 1 April 2017	200,000		1,652,837	8,804
Balance as at 31 March 2018	200,000		1,652,837	8,804
Balance as at 31 March 2019	200,000		1,652,837	8,804

b) Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) The details of shareholders holding more than 5% shares in the company

	No. of Shares	% of holdings in the class	No. of Shares	% of holdings in the class
Name of the shareholder				
Jubilant Life Sciences International Pte. Ltd., Singapore	200,000	100%	200,000	100%

Jubilant Life Sciences (Shanghai) Limited Notes to the financial statements for the year ended 31 March 2019

	RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
	As at 31	March 2019	As at 31 N	March 2018
Note 9. Trade payables				
Trade payables-others	13,377,440	137,654	18,941,615	196,614
	13,377,440	137,654	18,941,615	196,614
Note 10. Other current liabilities				
Statutory dues	19,224	198	29,195	303
	19,224	198	29,195	303

Notes to the financial statements for the year ended 31 March 2019

		INR (₹ In		INR (₹ In
	RMB	Thousands)	RMB	Thousands)
	For the y	ear ended	For the y	ear ended
	31 Mar	ch 2019	31 Mar	rch 2018
Note 11. Revenue from operations				
Sales of products	96,306,922	1,002,558	134,141,337	1,310,655
Revenue from operations	96,306,922	1,002,558	134,141,337	1,310,655
Note 12. Other income				
Interest income	12,611	132	23,885	231
Other non-operating income	4,435	46		740
	17,046	178	23,885	231
Note 13. Purchases of stock-in-trade				
Purchase of stock-in-trade	89,016,310	927,036	126,028,091	1,230,670
	89,016,310	927,036	126,028,091	1,230,670
Note 14. Changes in inventories of traded goods				
Stock at close - traded goods	15,894,289	163,552	12,671,002	117,753
	15,894,289	163,552	12,671,002	117,753
Stock at commencement - traded goods	12,671,002	129,560	11,267,975	105,919
	12,671,002	129,560	11,267,975	105,919
(Decrease) in stocks	3,223,287	33,992	1,403,027	11,834
Note 15. Employee benefits expense				
Salaries, wages, bonus, gratuity and allowances	3,988,642	41,523	3,340,900	32,534
Contribution to provident and superannuation fund	403,326	4,194	293,155	2,852
Staff welfare expenses	266,371	2,773	273,375	2,661
	4,658,339	48,490	3,907,430	38,047

Jubilant Life Sciences (Shanghai) Limited Notes to the financial statements for the year ended 31 March 2019

roces to the imanetal statements for the year orded 51 Ware	RMB	INR (₹ In Thousands)	RMB	INR (₹ In Thousands)
<u> </u>	For the y	ear ended ch 2019	For the y	ear ended ch 2018
Note 16. Finance costs				
Interest expense	586,020	6,102	850,256	8,345
	586,020	6,102	850,256	8,345
Note 17. Other expenses				
Rent	111,879	1,165	119,396	1,162
Rates and taxes	164,180	1,709	244,521	2,398
Insurance	90,286	911	98,536	966
Advertisement, publicity and sales promotion	16,499	171	18,070	178
Travelling and other incidental expenses	195,636	2,027	181,486	1,774
Repairs				
- Others	480	5	847	8
Office expenses	29,789	310	60,475	588
Printing and stationery	727	8	4,410	43
Communication expenses	155,980	1,623	190,030	1,854
Staff recruitment and training	545	6	300	3
Auditors Remuneration - As Auditors	69,904	728	53,611	517
Legal, professional and consultancy charges	384,420	3,981	225,966	2,191
Freight and forwarding (including ocean freight)	2,914,779	30,272	3,070,399	29,868
Subscription	102,955	1,064	255,718	2,509
Bank Charges	76,390	796	99,194	970
Discounts and claims to customer and other selling expenses	1,146,688	11,953	281,805	2,755
Commission on sales	240,940	2,527	(8,411)	(68)
Miscellaneous expenses	(13)	(0)	-	(6)
Foreign exchange (gain) /loss	932,088	9,686	(2,174,565)	(21,465)
	6,634,152	68,972	2,721,788	26,251
Note 18: Depreciation and amortisation expense				
Depreciation of property, plant and equipment	26,190	273	27,114	264
	26,190	273	27,114	264